SG Americas Securities LLC Grows Position in Aquestive Therapeutics, Inc. (NASDAQ:AQST)

SG Americas Securities LLC lifted its position in Aquestive Therapeutics, Inc. (NASDAQ:AQST) by 28.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 32,966 shares of the company’s stock after buying an additional 7,347 shares during the quarter. SG Americas Securities LLC’s holdings in Aquestive Therapeutics were worth $117,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. nVerses Capital LLC purchased a new stake in shares of Aquestive Therapeutics in the third quarter worth about $28,000. Harvey Capital Management Inc. purchased a new stake in shares of Aquestive Therapeutics in the third quarter worth about $88,000. Intech Investment Management LLC purchased a new stake in shares of Aquestive Therapeutics in the third quarter worth about $90,000. BNP Paribas Financial Markets lifted its holdings in shares of Aquestive Therapeutics by 252.2% in the third quarter. BNP Paribas Financial Markets now owns 18,826 shares of the company’s stock worth $94,000 after buying an additional 13,481 shares in the last quarter. Finally, International Assets Investment Management LLC purchased a new stake in shares of Aquestive Therapeutics in the third quarter worth about $990,000. 32.45% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research firms recently weighed in on AQST. HC Wainwright restated a “buy” rating and issued a $10.00 price objective on shares of Aquestive Therapeutics in a research report on Friday, December 20th. Cantor Fitzgerald began coverage on shares of Aquestive Therapeutics in a research report on Tuesday, December 17th. They issued an “overweight” rating and a $17.00 price objective on the stock. Finally, Leerink Partners upped their price objective on shares of Aquestive Therapeutics from $12.00 to $13.00 and gave the stock an “outperform” rating in a research report on Friday, October 25th. Six investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $11.00.

Aquestive Therapeutics Stock Performance

AQST stock opened at $2.97 on Wednesday. The company has a market capitalization of $270.80 million, a PE ratio of -6.60 and a beta of 2.67. Aquestive Therapeutics, Inc. has a one year low of $2.24 and a one year high of $6.23. The company’s 50 day moving average price is $3.41 and its two-hundred day moving average price is $4.21.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.